The Expression of Immune Checkpoint Receptors and Ligands in the Colorectal Cancer Tumor Microenvironment
Overview
Authors
Affiliations
Background/aim: The limited efficacy of immune checkpoint inhibitors in colorectal cancer (CRC) is likely due to immunosuppressive mechanisms including T cell exhaustion caused by inhibitory immune checkpoints in the tumor microenvironment.
Materials And Methods: We investigated the expression status of the inhibitory immune checkpoint receptors on tumor-infiltrating T cells and their ligands on tumor cells by flow cytometry and immunohistochemistry, using surgically-resected specimens of CRC.
Results: Flow cytometry analysis indicated that TIM-3, TIGIT, and PD-1 were expressed on tumor-infiltrating CD4+ (8.3%, 56.0%, 26.1%) and CD8+ T cells (8.2%, 51.6%, 23.5%), and CRC cells abundantly expressed PD-L1, CEACAM-1, and CD155 (2.2%, 77.0%, 46.8%). Immunohistochemical analysis revealed that the tumor proportional score of PD-L1, CEACAM-1, and CD155 was 42.4%, 54.2%, and 52.1%, respectively.
Conclusion: PD-1, TIM-3, and TIGIT axes may reduce T cell function in the CRC tumor microenvironment.
Effect of colorectal cancer stem cells on the development and metastasis of colorectal cancer.
Deng R, Zheng X, Lu Z, Yuan M, Meng Q, Wu T World J Gastrointest Oncol. 2024; 16(11):4354-4368.
PMID: 39554751 PMC: 11551631. DOI: 10.4251/wjgo.v16.i11.4354.
Zhang Y, Zhang C, Chen G, You H, Wang S, Wang X Transl Oncol. 2024; 46:102031.
PMID: 38861853 PMC: 11209639. DOI: 10.1016/j.tranon.2024.102031.
Ito M, Mimura K, Nakajima S, Okayama H, Saito K, Nakajima T Cancer Immunol Immunother. 2023; 72(7):2233-2244.
PMID: 36869896 PMC: 10992489. DOI: 10.1007/s00262-023-03406-6.
Ducoin K, Bilonda-Mutala L, Deleine C, Oger R, Duchalais E, Jouand N Cancers (Basel). 2022; 14(17).
PMID: 36077799 PMC: 9454990. DOI: 10.3390/cancers14174261.
Xu Y, Cao C, Zhu Z, Wang Y, Tan Y, Xu X Front Genet. 2022; 13:901734.
PMID: 35734431 PMC: 9208084. DOI: 10.3389/fgene.2022.901734.